The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 98-105

  Chen, Yiwen ^a   Bai, Xueli ^a   Zhang, Qi ^a   Wen, Liang ^a   Su, Wei ^a   Fu, Qihan ^a   Sun, Xu ^a   Lou, Yu ^a   Yang, Jiaqi ^a   Zhang, Jingying ^a   Chen, Qi ^a   Wang, Jianxin ^a   Liang, Tingbo ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

HBx; Migration; PI3K AKT signaling; Risk factor; Survival

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HEPATITIS B ANTIGEN; HEPATITIS B VIRUS X PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR ALPHA; VIRUS DNA; ERBB4 PROTEIN, HUMAN; HEPATITIS B SURFACE ANTIGEN; PROTEIN KINASE INHIBITOR; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER CELL LINE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PDAC CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, PANCREATIC DUCTAL; CELL MOTION; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HEPATITIS B VIRUS; KAPLAN MEIER METHOD; METABOLISM; PANCREATIC NEOPLASMS; PATHOGENICITY; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE; VIROLOGY; VIRUS CELL TRANSFORMATION;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KAPLAN-MEIER ESTIMATE; PANCREATIC NEOPLASMS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-4; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84975883326     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.06.011     Document Type: Article

References (43)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics. CA Cancer J. Clin 66 (2016), 7–30.
2. [2] Wolfgang, C.L., Herman, J.M., Laheru, D.A., Klein, A.P., Erdek, M.A., Fishman, E.K., et al. Recent progress in pancreatic cancer. CA Cancer J. Clin 63 (2013), 318–348.
3. [3] Fiorino, S., Lorenzini, S., Masetti, M., Deleonardi, G., Grondona, A.G., Silvestri, T., et al. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Med. Hypotheses 79 (2012), 678–697.
4. [4] Schottenfeld, D., Beebe-Dimmer, J., Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin 56 (2006), 69–83.
5. [5] Hussain, S.P., Harris, C.C., Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121 (2007), 2373–2380.
6. [6] Trikudanathan, G., Philip, A., Dasanu, C.A., Baker, W.L., Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 12 (2011), 26–31.
7. [7] Xiao, M., Wang, Y., Gao, Y., Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS ONE, 8, 2013, e75559.
8. [8] Xu, J.H., Fu, J.J., Wang, X.L., Zhu, J.Y., Ye, X.H., Chen, S.D., Hepatitis B or C viral infection and risk of pancreatic cancer: a meta-analysis of observational studies. World J. Gastroenterol 19 (2013), 4234–4241.
9. [9] Fiorino, S., Cuppini, A., Castellani, G., Bacchi-Reggiani, M.L., Jovine, E., HBV- and HCV-related infections and risk of pancreatic cancer. JOP 14 (2013), 603–609.
10. [10] Wang, Y., Yang, S., Song, F., Cao, S., Yin, X., Xie, J., et al. Hepatitis B virus status and the risk of pancreatic cancer: a meta-analysis. Eur. J. Cancer Prev 22 (2013), 328–334.
11. [11] Luo, G., Hao, N.B., Hu, C.J., Yong, X., Lu, M.H., Cheng, B.J., et al. HBV infection increases the risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 24 (2013), 529–537.
12. [12] Hassan, M.M., Li, D., El-Deeb, A.S., Wolff, R.A., Bondy, M.L., Davila, M., et al. Association between hepatitis B virus and pancreatic cancer. J. Clin. Oncol 26 (2008), 4557–4562.
13. [13] Wang, D.S., Wang, Z.Q., Zhang, L., Qiu, M.Z., Luo, H.Y., Ren, C., et al. Are risk factors associated with outcomes in pancreatic cancer?. PLoS ONE, 7, 2012, e41984.
14. [14] Wei, X.L., Qiu, M.Z., Chen, W.W., Jin, Y., Ren, C., Wang, F., et al. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J. Transl. Med, 11, 2013, 249.
15. [15] Xing, S., Li, Z.W., Tian, Y.F., Zhang, L.M., Li, M.Q., Zhou, P., et al. Chronic hepatitis virus infection increases the risk of pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat. Dis. Int 12 (2013), 575–583.
16. [16] Fiorino, S., Chili, E., Bacchi-Reggiani, L., Masetti, M., Deleonardi, G., Grondona, A.G., et al. Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: a systematic review and meta-analysis. Pancreatology 13 (2013), 147–160.
17. [17] Ben, Q., Li, Z., Liu, C., Cai, Q., Yuan, Y., Wang, K., et al. Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. Pancreas 41 (2012), 435–440.
18. [18] Wang, D.S., Chen, D.L., Ren, C., Wang, Z.Q., Qiu, M.Z., Luo, H.Y., et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int. J. Cancer 131 (2012), 461–468.
19. [19] Iloeje, U.H., Yang, H.I., Jen, C.L., Su, J., Wang, L.Y., You, S.L., et al. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 30 (2010), 423–429.
20. [20] Zhu, F., Li, H.R., Du, G.N., Chen, J.H., Cai, S.R., Chronic hepatitis B virus infection and pancreatic cancer: a case-control study in southern China. Asian Pac. J. Cancer Prev 12 (2011), 1405–1408.
21. [21] Andersen, E.S., Omland, L.H., Jepsen, P., Krarup, H., Christensen, P.B., Obel, N., et al. Risk of all-type cancer, hepatocellular carcinoma, non-Hodgkin lymphoma and pancreatic cancer in patients infected with hepatitis B virus. J. Viral Hepat 22 (2015), 828–834.
22. [22] Tang, J., Sharma, R., Lamerato, L., Sheehan, M., Krajenta, R., Gordon, S.C., Is previous exposure to hepatitis B a risk factor for pancreatic cancer or hepatocellular carcinoma?. J. Clin. Gastroenterol 48 (2014), 729–733.
23. [23] Hong, S.G., Kim, J.H., Lee, Y.S., Yoon, E., Lee, H.J., Hwang, J.K., et al. [The relationship between hepatitis B virus infection and the incidence of pancreatic cancer: a retrospective case-control study]. Korean J. Hepatol 16 (2010), 49–56.
24. [24] Abe, S.K., Inoue, M., Sawada, N., Iwasaki, M., Shimazu, T., Yamaji, T., et al. Hepatitis B and C virus infection and risk of pancreatic cancer: a population-based cohort study (JPHC Study Cohort II). Cancer Epidemiol. Biomarkers Prev, 2015, 10.1158/1055-9965.EPI-15-1115.
25. [25] Jin, Y., Gao, H., Chen, H., Wang, J., Chen, M., Li, G., et al. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett 335 (2013), 447–454.
26. [26] Lang, Z.W., Yan, H.P., Huang, D.Z., [Detection of HBV DNA in extrahepatic tissue with PCR comparison with immunohistochemistry and in situ hybridization]. Zhonghua Nei Ke Za Zhi 33 (1994), 232–236.
27. [27] Yoshimura, M., Sakurai, I., Shimoda, T., Abe, K., Okano, T., Shikata, T., Detection of HBsAg in the pancreas. Acta Pathol. Jpn 31 (1981), 711–717.
28. [28] Benhenda, S., Cougot, D., Buendia, M.A., Neuveut, C., Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv. Cancer Res 103 (2009), 75–109.
29. [29] Tsuge, M., Hiraga, N., Akiyama, R., Tanaka, S., Matsushita, M., Mitsui, F., et al. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice. J. Gen. Virol 91 (2010), 1854–1864.
30. [30] Unger, T., Shaul, Y., The X protein of the hepatitis B virus acts as a transcription factor when targeted to its responsive element. EMBO J. 9 (1990), 1889–1895.
31. [31] Clippinger, A.J., Gearhart, T.L., Bouchard, M.J., Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore. J. Virol 83 (2009), 4718–4731.
32. [32] Hino, O., Kitagawa, T., Koike, K., Kobayashi, M., Hara, M., Mori, W., et al. Detection of hepatitis B virus DNA in hepatocellular carcinomas in Japan. Hepatology 4 (1984), 90–95.
33. [33] Fiorino, S., Visani, M., Acquaviva, G., Fornelli, A., Masetti, M., Cuppini, A., et al. Search for HBV and HCV Genome in Cancer Cells of Pancreatic Tumors. Pancreas 45 (2016), e12–e14.
34. [34] Zhang, Q., Bai, X., Chen, W., Ma, T., Hu, Q., Liang, C., et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 34 (2013), 962–973.
35. [35] Semba, S., Itoh, N., Ito, M., Harada, M., Yamakawa, M., The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin. Cancer Res 8 (2002), 1957–1963.
36. [36] Hu, L., Zaloudek, C., Mills, G.B., Gray, J., Jaffe, R.B., In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res 6 (2000), 880–886.
37. [37] Raimondo, G., Pollicino, T., Romano, L., Zanetti, A.R., A 2010 update on occult hepatitis B infection. Pathol. Biol. (Paris) 58 (2010), 254–257.
38. [38] He, S., Su, C., Shen, L., Niu, J., [Occult hepatitis B virus infection in normal population, Xiamen]. Zhonghua Yu Fang Yi Xue Za Zhi 49 (2015), 132–136.
39. [39] Zhang, X., You, X., Wang, Q., Zhang, T., Du, Y., Lv, N., et al. Hepatitis B virus X protein drives multiple cross-talk cascade loops involving NF-kappaB, 5-LOX, OPN and Capn4 to promote cell migration. PLoS ONE, 7, 2012, e31458.
40. [40] Yuan, T.L., Cantley, L.C., PI3K pathway alterations in cancer: variations on a theme. Oncogene 27 (2008), 5497–5510.
41. [41] Mukherji, A., Janbandhu, V.C., Kumar, V., HBx protein modulates PI3K/Akt pathway to overcome genotoxic stress-induced destabilization of cyclin D1 and arrest of cell cycle. Indian J. Biochem. Biophys 46 (2009), 37–44.
42. [42] Sanjit, K., Roy, R.K.S., Shankar, S., Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J. Mol. Signal, 5, 2010.
43. [43] Williams, T.M., Flecha, A.R., Keller, P., Ram, A., Karnak, D., Galbán, S., et al. Co-targeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Mol. Cancer Ther 11 (2012), 1193–1202.